GlassScriptPhysician profile
Kwok-Man Lee
NPI 1538262464
$23,160.45
in general payments reported to CMS, 2019-2025
36 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,682 · 2020: $2,419 · 2021: $4,496 · 2022: $3,404 · 2023: $2,673 · 2024: $3,103 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,142 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,141.93 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,177.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,845.74 | 2019-2025 | Jardiance, Stiolto Respimat |
| Novo Nordisk INC | $2,142.53 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $2,133.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Lilly USA, LLC | $1,115.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,112.92 | 2019-2024 | Otezla, Repatha, Prolia |
| Gilead Sciences, INC. | $887.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $717.96 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $624.92 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $545.19 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $449.05 | 2021-2025 | |
| Amarin Pharma, INC. | $403.60 | 2019-2023 | |
| Abbvie INC. | $281.17 | 2022-2025 | |
| Esperion Therapeutics, INC. | $279.27 | 2020-2024 | Nexletol |
| Opko Pharmaceuticals, LLC | $276.74 | 2020-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwok-Man Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.